WALTHAM, Mass., June 8 /PRNewswire/ -- Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced today that it has signed an agreement with Fujitsu Limited that allows them to jointly market InForm J(TM), the Japanese version of Phase Forward's InForm(TM) electronic data capture (EDC) product -- to the Japanese pharmaceutical, biotechnology and medical devices sector. The agreement enables Fujitsu to provide its customers with the software, services, and support needed to perform EDC for clinical trials.
Phase Forward believe that this new approach will mark the beginning of significant growth of e-clinical trials in Japan. Customers using InForm(TM) in other regions have demonstrated it can compress trial times, reduce the cost and improve the quality of data, compared to traditional paper-based data capture methods. In readiness for this expected growth and by way of commitment to this regional development of EDC, Phase Forward has translated its products into Japanese and has enhanced its operation in Tokyo, which has been providing product, services and support to the Japanese market for over 13 years.
Steve Powell, International Vice President from Phase Forward commented, "Fujitsu's adoption of InForm highlights the growing demand within the Japanese market for real-time, accurate data management in clinical trials. This deal will enable Fujitsu to develop a best practice approach to clinical trials particularly suited to the high volume patient recruitment typical of Japanese trials. As a result we expect this market to experience growth in the number and size of clinical trials taking place."
Kenji Sata, General Manager of Life Sciences Systems Division, Healthcare Solutions Group of Fujitsu Limited said, "Japan is an important growth market for companies in the pharmaceutical, biotech, and medical devices industries. Fujitsu can now offer these companies with strategic subsidiaries in Japan a one-stop integrated management solution to help execute clinical studies, by combining InForm J with Fujitsu's Internet Data Center services, reliable servers, computing products, and support network throughout Japan. We are confident that the introduction of InForm J will lead to the successful implementation of EDC in the Japan market."
Phase Forward's InForm EDC solution is a leading global electronic data capture system that delivers streamlined data collection and real-time query resolution that is essential for high-volume clinical trials.
The InForm(TM) system enables:
-- Rapid data entry and cleaning through intuitive user interface
-- Extensive data checking
-- Automated query processing
-- Immediate access to all clinical and trial data for earlier and ongoing
-- Scalable Internet-based architecture, supporting high-volume, global
-- Streamlined data collection and query resolution
-- 24 x 7 Global Customer Support
Notes to Editors
About Phase Forward:
Phase Forward is a leading provider of integrated enterprise-level software products, services, and hosted solutions for use in the clinical trial component of its customers' global research and development initiatives. Phase Forward's customers include pharmaceutical, biotechnology, and medical device companies, as well as academic institutions, clinical research organisations, and other entities engaged in clinical trials. By automating essential elements of the clinical trial process, the company believes its products allow its customers to accelerate the market introduction of new medical therapies and corresponding revenue, reduce overall research and development expenditures, enhance existing data quality control efforts, and reduce clinical and economic risk. Phase Forward believes its enterprise software and hosted solutions are the most widely adopted commercial electronic data capture, data management, and adverse event reporting solutions in the clinical trial marketplace, having been utilised in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants and 300 therapeutic compounds and medical devices. Phase Forward's customer base of over 220 customers is comprised of the leading pharmaceutical, biotechnology, medical device, and clinical research organisations, including AstraZeneca Pharmaceuticals LP, Guidant Corporation, Eli Lilly and Company, Novartis AG, and Schering-Plough Research Institute. Phase Forward is headquartered in Waltham, Massachusetts with offices in the United Kingdom, Australia, France, and Japan. Additional information about Phase Forward is available at http://www.phaseforward.com/.
For more information about Fujitsu, please see: http://www.fujitsu.com/ /